Annual Review 2012

Invion Limited is a clinical-stage drug development company that targets chronic inflammation. The company is focused on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus. Invion has two phase II proprietary therapeutic candidates:

INV102 – a repurposed beta adrenergic inverse agonist; and
Cpn10 – a modified natural immunomodulator.

Download our 2012 Annual Review below –

Posted in Annual Review, ASX Releases